Skip to main content
SpringerLink
Log in

Tiotropium Respimat® Soft Mist™ inhaler: a guide to its use in chronic obstructive pulmonary disease (COPD) in the EU

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Tiotropium Respimat® Soft Mist™ inhaler (Spiriva® Respimat®) is indicated as a maintenance bronchodilator to relieve the symptoms of patients with chronic obstructive pulmonary disease (COPD) in the EU. The delivered drug dose is independent of inspiratory effort and the prolonged duration of the aerosol cloud should make the co-ordination of actuation and inhalation easier. In patients with COPD, tiotropium Respimat® improved lung function, COPD exacerbations, health-related quality of life and dyspnoea, and was generally well tolerated. Relative to administration of tiotropium via the HandiHaler®, administration of the drug via the Respimat® Soft Mist™ inhaler improves lung deposition of the drug (allowing a lower nominal dose to be used), is at least as effective, and has a similar tolerability profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: updated 2014. Bethesda: Global Initiative for Chronic Obstructive Lung Disease; 2014.

  2. Human medicines: European public assessment reports. London: European Medicines Agency; 2014.

  3. Barnes PJ. The pharmacological properties of tiotropium. Chest. 2000;117(2 Suppl):63S–6S.

    Article  CAS  PubMed  Google Scholar 

  4. Tautermann CS, Kiechle T, Seeliger D, et al. Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor. J Med Chem. 2013;56(21):8746–56.

    Article  CAS  PubMed  Google Scholar 

  5. Spiriva (tiotropium) Respimat 2.5 micrograms, inhalation solution: EU summary of product characteristics. Ingelheim am Rhein: Boehringer Ingelheim International GmbH; 2014.

  6. Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs. 2012;72(2):273–300.

    Article  PubMed  Google Scholar 

  7. Dalby R, Spallek M, Voshaar T. A review of the development of Respimat® Soft Mist™ Inhaler. Int J Pharm. 2004;283(1–2):1–9.

    Article  CAS  PubMed  Google Scholar 

  8. Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med. 1999;12(Suppl 1):S19–24.

    PubMed  Google Scholar 

  9. Hochrainer D, Hölz H, Kreher C, et al. Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist™ inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18(3):273–82.

    Article  CAS  PubMed  Google Scholar 

  10. Pitcairn G, Reader S, Pavia D, et al. Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ inhaler compared to deposition by metered dose inhaler or by Turbuhaler® dry powder inhaler. J Aerosol Med. 2005;18(3):264–72.

    Article  CAS  PubMed  Google Scholar 

  11. Newman SP, Steed KP, Reader SJ, et al. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci. 1996;85(9):960–4.

    Article  CAS  PubMed  Google Scholar 

  12. Hohlfeld JM, Sharma A, van Noord JA, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54(4):405–14.

    Article  CAS  PubMed  Google Scholar 

  13. Newman SP, Steed KP, Reader SJ, et al. An in vitro study to assess facial and ocular deposition from Respimat® Soft Mist™ inhaler. J Aerosol Med. 2007;20(1):7–12.

    Article  CAS  PubMed  Google Scholar 

  14. Caillaud D, Le Merre C, Martinat Y, et al. A dose-ranging study of tiotropium delivered via Respimat® Soft Mist Inhaler™ or HandiHaler® in COPD patients. Int J Chron Obstruct Pulm Dis. 2007;2(4):559–65.

    CAS  Google Scholar 

  15. van Noord JA, Cornelissen PJG, Aumann J-L, et al. The efficacy of tiotropium administered via Respimat® Soft Mist Inhaler™ or HandiHaler® in COPD patients. Respir Med. 2009;103(1):22–9.

    Article  PubMed  Google Scholar 

  16. Voshaar T, Lapidus R, Maleki-Yazdi R, et al. A randomized study of tiotropium Respimat® Soft Mist™ inhaler vs. ipratropium pMDI in COPD. Respir Med. 2008;102(1):32–41.

    Article  CAS  PubMed  Google Scholar 

  17. Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5 μg via Respimat and 18 μg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med. 2010;104(2):228–36.

    Article  CAS  PubMed  Google Scholar 

  18. Bateman E, Singh D, Smith D, et al. Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulm Dis. 2010;5:197–208.

    CAS  Google Scholar 

  19. Bateman ED, Tashkin D, Siafakas N, et al. A 1-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir Med. 2010;104(10):1460–72.

    Article  CAS  PubMed  Google Scholar 

  20. Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–501.

    Article  CAS  PubMed  Google Scholar 

  21. Tashkin D, Metzdorf N, Hallmann C, et al. Safety of tiotropium in renally impaired patients [abstract no. P923 plus poster]. In: European Respiratory Society International Congress. 2014.

  22. Feifel U, Wallenstein G, Rominger K-L, et al. Pharmacokinetics and tolerability (study 1) with particular reference to ocular safety (study 2) of tiotropium Respimat® Soft Mist Inhaler™: findings from two dose-ranging studies in healthy men. Int J Chron Obstruct Pulm Dis. 2008;3(3):397–403.

    CAS  Google Scholar 

  23. Calverley P, Könen-Bergmann M, Metzdorf N, et al. Tiotropium Respimat®: comparison of bronchodilator efficacy of 5- and 2.5-μg doses [abstract no. P924 plus poster]. In: European Respiratory Society International Congress. 2014.

  24. Rau-Berger H, Mitfessel H, Glaab T. Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulm Dis. 2010;5:367–73.

    Article  CAS  Google Scholar 

  25. Hodder R, Pavia D, Lee A, et al. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD. Int J Chron Obstruct Pulm Dis. 2011;6:245–51.

    Article  Google Scholar 

  26. Mathioudakis AG, Chatzimavridou-Grigoriadou V, Evangelopoulou E, et al. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent? Pulm Pharmacol Ther. 2014;28(2):91–7.

    Article  CAS  PubMed  Google Scholar 

  27. Halpin D, Dahl R, Hallmann C, et al. Tiotropium Handihaler® and Respimat® in COPD: a safety analysis on pooled data [abstract]. In: American Thoracic Society International Conference. 2014.

  28. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54.

    Article  CAS  PubMed  Google Scholar 

  29. Pharmacovigilance Risk Assessment Committee (PRAC): minutes of the meeting on 5–8 May 2014. London: European Medicines Agency; 2014.

  30. Bateman ED. Improving inhaler use in COPD and the role of patient preference. Eur Respir Rev. 2005;14(96):85–8.

    Article  Google Scholar 

  31. Anderson P. Use of Respimat® Soft Mist™ Inhaler in COPD patients. Int J Chron Obstruct Pulm Dis. 2006;1(3):251–9.

    CAS  Google Scholar 

  32. Fink JB, Colice GL, Hodder R. Inhaler devices for patients with COPD. COPD. 2013;10(4):523–35.

    Article  PubMed  Google Scholar 

  33. Asakura Y, Nishimura N, Maezawa K, et al. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. J Aerosol Med Pulm Drug Deliv. 2013;26(1):41–5.

    Article  CAS  PubMed  Google Scholar 

  34. Keating GM. Tiotropium Respimat® Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs. 2014;74(15):1801–16.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The manuscript was reviewed by: S.A. Antoniu, University of Medicine and Pharmacy Grigore T Popa Iasi, Department of Interdisciplinary-Pallistive Care Nursing, Iasi, Romania; C. Incorvaia, Pulmonary Rehabilitation Unit, Instuti Clinici de Perfezionamento, Presidio Ospedaliero CTO, Milan, Italy; R. Janknegt, Orbis Medical Centre, Sittard-Geleen, The Netherlands; R.B. Shah, Department of Pharmacology, GMERS Medical College and Hospital, Gandhinagar, Gujarat, India

Disclosure

This article was adapted from Drugs 2014;74(15):1801–16 by salaried employees of Adis/Springer [34]. The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson & Gillian M. Keating

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A., Keating, G.M. Tiotropium Respimat® Soft Mist™ inhaler: a guide to its use in chronic obstructive pulmonary disease (COPD) in the EU. Drugs Ther Perspect 31, 39–44 (2015). https://doi.org/10.1007/s40267-014-0181-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-014-0181-x

Keywords

Search

Navigation